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Abstract 
Background: Point-of-care testing for C-reactive protein (CRP) may be helpful in 
differentiating viral from bacterial infection. Such a device should give results 
comparable to laboratory testing. The aim was to evaluate two point-of-care CRP tests 
(Nycocard and QuikRead) in febrile children in general practice, compared to a reference 
immunoturbidimetric assay. 
Methods: Cross-sectional study of febrile children aged 3 months to 6 years presented to 
a general practice out-of-hours service. Children were visited at home, where blood was 
taken for the tests, within 24 hours of presentation. The Nycocard test was performed at 
home, whereas the QuikRead and reference test were performed in the laboratory. 
Results: 76 children were enrolled. All three CRP tests were performed in 59 children. 
The mean difference between the reference test and Nycocard and QuikRead was 0.6 
mg/L and –6.1 mg/L, respectively. The slopes of the Passing and Bablok regression were 
0.95 (95% CI 0.9-1.0) and 0.83 (95% CI 0.81-0.85) for Nycocard and QuikRead, 
respectively. 
Conclusion: Up to a concentration of 160 mg/L the Nycocard correlated well with the 
reference test, while the QuikRead underestimated concentrations above 60 mg/L. The 
Nycocard test seems a good candidate for CRP point-of-care testing in general practice.  
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Introduction 
Fever is very common among children in general practice (1). Febrile children are 
often presented in the evening, outside normal office hours and are therefore mostly seen 
in general practice out-of-hours services. Fever generally has no serious consequences, 
but approximately 1% of children develop a serious bacterial infection (SBI), e.g. 
pneumonia or meningitis, with possible life-threatening complications (2, 3). Early 
recognition and treatment of SBI leads to a better prognosis (4, 5). Differentiating the few 
bacterial infections from the bulk of self-limiting viral infections in febrile children is a 
great challenge for general practitioners. 
The use of near-patient or point-of-care testing (POCT) for C-reactive protein (CRP) 
measurement in general practice has the advantage of providing the result within minutes, 
making early diagnosis and management of bacterial infections possible. Such POCT 
devices should give results comparable to reference testing and be feasible to use in daily 
practice.   
CRP is the first described acute phase protein, produced by hepatocytes as part of the 
non-specific acute phase response to infection, inflammation and tissue damage (6). CRP 
values in healthy individuals are below 10 mg/L. After the onset of inflammation or 
tissue injury, CRP concentration increases rapidly in the first six hours, reaches maximal 
levels after approximately 48 hours and falls rapidly when stimulation ends. Therefore, 
CRP serves as a very useful marker in screening for infectious and inflammatory diseases 
as well as for monitoring the response to treatment or disease activity (6, 7).  
The aim of this study was to evaluate two different POCT devices for CRP 
measurement, the Nycocard CRP and the QuikRead CRP, in febrile children presented to 
a general practice out-of-hours service.  
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Materials and methods 
Patients 
Febrile children, aged three months to six years, presented at a general practice out-
of-hours service in Rotterdam on Monday to Thursday evenings were eligible for the 
study. Children were enrolled between March 7th and May 31st, 2005.  
The receptionist of the service questioned the parents about the fever of the child. 
The parents were informed about the study and were visited at home by a research 
assistant within 24 hours. During the home visit, the parents answered a structured 
questionnaire and the child was physically examined following a structured scheme. A 
finger prick in the middle finger was performed according to the NCCLS protocol (8). 
The obtained capillary blood was immediately used to perform the Nycocard CRP test. 
Another 400 μL of blood was drawn in heparin microtainers. Subsequently, the tubes 
were centrifuged and plasma was stored at -20ºC until measurement. 
Parents gave written informed consent. Children resisting physical examination or 
the finger prick were not enrolled. The Dutch Central Committee on Research involving 
Human Subjects (CCMO) approved the study. 
Primary outcome measure 
The primary outcome measure was the difference between the CRP value measured 
by the reference test and the POCT CRP tests, in mg/L. 
CRP tests 
For the Nycocard CRP test (Clindia Diagnostics, Leusden, the Netherlands) 5 μL 
whole blood was taken to determine the CRP value in mg/L, using the Nycocard test kit. 
Two medical students performed all measurements. The medical students were trained by 
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highly qualified laboratory technicians of the department of clinical chemistry during five 
sessions before performing the Nycocard CRP test in children.  
The QuikRead CRP test (Orion Corporation, Orion Diagnostica, Espoo, Finland) has 
been evaluated on the QuikRead System for both whole blood (20 μL) and plasma. In our 
evaluation protocol this CRP test was performed with plasma by trained laboratory 
technicians who were blinded for the results of the reference test, the Nycocard test and 
patient characteristics. 20 μL plasma was used to determine the CRP value in mg/L. 
For the reference CRP test, the Tina-quant CRP Hitachi 912 (Roche Diagnostics, 
Penzberg, Germany) was used, which has been standardized against the CRM 470 (9). 
All plasma samples were analyzed in one batch after the enrollment period and laboratory 
technicians were blinded for the POCT CRP results. 
Patient characteristics 
Since the medical students were not blinded for patient characteristics, the Nycocard 
CRP results may be influenced by characteristics of the children such as gender, height of 
the fever, duration of fever at the moment of the CRP measurement, and an “illness 
score”. This latter score is a measure of the first impression of the general condition or 
illness of the child. It is categorized into not ill, slightly ill, moderately ill and seriously 
ill. These characteristics were assessed during the home visit. 
Statistical analysis 
The linear association between the results given by the POCT CRP tests and the 
reference test was analyzed using Pearson’s correlation coefficient. The agreement 
between the results was analyzed with the intraclass correlation coefficient (ICC). The 
ICC produces measures of agreement of values within cases and ranges from 0 to 1. An 
ICC of 0.8 is accepted as a good agreement (10). 
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 The differences between the POCT CRP tests and the reference test were analyzed 
using the Bland and Altman method (11) and the Passing and Bablok regression (12). We 
considered the POCT CRP test clinically valid when results did not deviate more than 10 
mg/L from the results of the reference test in the concentration range of 0-70 mg/L.  
The non-parametrical Mann-Whitney test was used to test the relationship of the 
patient characteristics gender, body temperature, duration of fever and illness score, with 
the difference between the POCT CRP tests and the reference test. Body temperature was 
dichotomized at 38°C, duration of fever at 24 hours, and illness score at not ill versus ill 
(slightly, moderately and seriously ill). 
Assuming an ICC of 0.9 a minimum of 46 individuals had to be included to reject the 
null hypothesis of ICC 0.8 with α =0.05 and a power of 80%. 
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Results 
During the enrollment period 76 children were visited. In 15 children CRP values 
could not be measured by the reference test due to insufficient material. Main reasons for 
insufficient material were no consent for the finger prick and resistance of the child. The 
results of 61 and 59 children were analyzed for Nycocard CRP and QuikRead CRP 
measurement, respectively. Rectal temperature could not be measured in two children 
and temperature was measured axillary in another child.  
Characteristics of the 76 enrolled children are presented in Table 1. The median age 
was 21 months (ranging from 3 to 71 months). The 61 children with full CRP data tended 
to be older, more often male and to have a longer duration of fever. The median height of 
the fever in these 61 children was 37.7ºC (ranging from 34.8 to 39.9ºC) and did not differ 
from the children lacking reference CRP data. 
 
TABLE 1 
 
Agreement 
The correlation coefficients of both CRP tests with the reference test were 0.99. The 
overall ICC value as well as the ICC value in the concentration range of 0-70 mg/L was 
0.99 for Nycocard, whereas both ICC values were 0.98 for QuikRead.  
Bland and Altman analysis 
The overall mean difference between the Nycocard CRP test and the reference test 
was 0.6 mg/L (n =61; 2 SD 19.7). In the concentration range of 0-70 mg/L the mean 
difference was 1.4 mg/L (n =46; 2 SD 11) and in the concentrations above 70 mg/L the 
mean difference was -1.9 mg/L (n =15; 2 SD 35.4). The overall mean difference between 
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the QuikRead test and the reference test was -6.1 mg/L (n =59; 2 SD 31.3). In the 
concentration range 0-70 mg/L the mean difference was -0.4 mg/L (n =46; 2 SD 11.8) 
and in the concentrations above 70 mg/L the mean difference was -26.4 mg/L (n =13; 2 
SD 44). The Bland and Altman plots are presented in Figure 1. 
Of the Nycocard results, 89% fell within -10 mg/L or +10 mg/L of the reference test 
results. In the concentration range of 0-70 mg/L, the maximum difference was exceeded 
in 2 out of 46 results (4.3%), by 14 and 24 mg/L. Of the QuikRead results, 78% fell 
within -10 mg/L or +10 mg/L of the reference test results. In the concentration range of 
0-70 mg/L, the maximum difference was exceeded in 2 out of 46 results (4.3%), by -15 
and -28 mg/L. 
 
FIGURE 1 
 
Passing and Bablok analysis 
 The intercept of the Nycocard and reference test comparison was 2.3 (95% CI 
1.0-3.4) with a slope of 0.95 (95% CI 0.9-1.0). The cusum test p-value was between 0.01 
and 0.05. In the QuikRead and reference test comparison the intercept was 3.9 (95% CI 
3.3-4.6) with a slope of 0.83 (95% CI 0.81-0.85). The cusum test p-value was >0.1. The 
plots are presented in Figure 2. 
 
FIGURE 2 
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Patient characteristics 
None of the patient characteristics gender, duration and height of fever and illness 
score was related to the differences between the reference test and the Nycocard test (p-
values 0.23-0.73). The distribution of CRP values for each of the three tests in the illness 
score categories not ill, slightly ill and ill (six moderately ill and one seriously ill) is 
presented in Figure 3.  
 
FIGURE 3 
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Discussion 
In this study two CRP POCT devices for clinical use in febrile children in general 
practice were compared to a routinely used laboratory method. Overall the Nycocard 
CRP test correlated well with the reference test, while the QuikRead CRP test 
underestimated the reference test above the concentration of 60 mg/L.  
The Bland and Altman plot of the Nycocard test shows a good correlation with the 
reference test up to a CRP concentration of 160 mg/L with only three outliers, but a 
substantial increase in distribution with deviations of more than 10 mg/L above a 
concentration of around 200 mg/L. The plot of the QuikRead test shows a smaller 
distribution up to a concentration of 60 mg/L compared to the Nycocard, but an 
increasing distribution above 40 mg/L with deviations of more than 10 mg/L above 60 
mg/L. Furthermore, the Passing & Bablok comparison shows a small constant bias in 
both tests, with a larger distribution in the lower concentration range for the Nycocard. 
However, the slope of the regression line of QuikRead indicates a proportional bias as 
well, indicating that the QuikRead deviation from the reference test increases with 
increasing CRP values, whereas the Nycocard deviation from the reference test is not 
dependent on the CRP values (up to 160 mg/L). 
Both tests show less precise measurement of CRP values in the higher concentration 
range. Most uncertainty in distinguishing viral from bacterial infection exists between 
CRP concentrations of 10 and 70 mg/L (13-15). A deviance in CRP concentration of 10 
mg/L of the reference test in this clinically relevant range may change the management of 
the febrile child (16), therefore the POCT device needs to correlate well in this 
concentration range. In the clinically relevant range the maximum difference was 
exceeded in only 4.3% in both tests.  
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  The Nycocard test produced higher values than the reference test, overall as well as 
in the case of outliers in the concentration range of 0-70 mg/L. The QuikRead, however, 
produced increasingly lower values than the reference test above 40 mg/L, which is in the 
clinically relevant range. Possible consequences of this imprecision in daily practice may 
be more unnecessary prescription of antibiotics and more hospital referral using the 
Nycocard, or missing children with bacterial infection using the QuikRead test. 
Randomized controlled trials are needed to evaluate the possible consequences.  
Medical students performed the Nycocard test during home visits in general practice, 
whereas experienced personnel in the laboratory performed the QuikRead test. This could 
explain the larger distribution with Nycocard in the 0-70 mg/L range and this might 
indicate that QuikRead would perform less in daily practice. However, overall the 
QuikRead test would be expected to perform better in the laboratory by trained 
technicians compared to the Nycocard test performed at home.  
The Nycocard CRP test can be carried out within 5 minutes using only 5 μL whole 
blood, whereas the QuikRead test requires first a dilution of 20 μL whole blood with 1 
mL of buffer after which a blank measurement is needed. Although we did not evaluate 
the use of the QuikRead System at home, the use of Nycocard at home seems to be more 
feasible because fewer actions are needed. 
The patient characteristics height and duration of fever, gender and ill score were not 
related to the difference between the Nycocard CRP value and the reference CRP value. 
Thus, when CRP measurement is performed on a POCT device by a general practitioner 
or assistant these variables do not seem to influence the results.  
Our results were in accordance with the results of other studies with the Nycocard 
device. Most studies concluded that use of the Nycocard was acceptable for POCT (17-
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19). Our results for QuikRead were different from previous studies. We are aware of two 
studies evaluating QuikRead, one in general practice (20) and one in the emergency room 
setting (21). Seamark et al. tested the device in patients referred with a variety of 
conditions and found a mean difference of 1 mg/L, with 95% of the POCT results within 
±10 mg/L of the mean value; the age of the patients is not given. Esposito et al. 
concluded that QuikRead and the standard reference assay showed similar median CRP 
levels and similar distribution of values. Both studies concluded that QuikRead 
performed reliably compared to a reference method. Taking into account the increasing 
underestimation of CRP values above 60 mg/L and the more labor-intensive method, we 
feel that, although not tested in daily practice, QuikRead is less suitable for CRP testing 
in general practice or an emergency room setting and more suitable for the laboratory 
setting. 
The use of CRP as a diagnostic marker for SBI has been studied and debated 
extensively. Several studies indicate that an increased CRP concentration is related to a 
higher risk of SBI in febrile children (14-16, 22). However, the management of febrile 
children by the general practitioner should not be based only on a CRP value, but also on 
other grounds e.g. clinical presentation, duration of symptoms and medical history. Our 
results show that the elevation of CRP concentration tends to be higher and the 
distribution of CRP values to be more widespread among febrile children who appear ill 
compared to children who appear well. In order to determine the effect of CRP POCT on 
clinical decision-making, further large prospective studies are needed (23). In addition, 
high quality diagnostic studies are needed to clarify the added diagnostic value of CRP 
along with other variables in differentiating bacterial from viral infections.  
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The use of POC CRP tests in general practice for early diagnosis and management of 
febrile children is promising. We feel that the Nycocard CRP test is a good candidate to 
meet this purpose.  
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Table 1: Characteristics of the 76 participating children, of whom 61 had full CRP data 
and 15 lacked reference CRP data 
 
Characteristics Children with full       Children lacking  
CRP data                     reference CRP data 
n =61                           n =15
Median age in months (range)  
Median height of fever in ºC (range) 
Median duration of fever in hours (range) 
 
Male gender  
Illness score 0  (not ill) 
Illness score I   (slightly ill) 
Illness score II  (moderately ill) 
Illness score III (seriously ill) 
21     (4-71)                14     (3-49) 
37.7  (34.8-39.9)        37.6  (36.4-39.8) 
48     (12-186)             24     (12-84) 
n     (%)                       n    (%) 
37   (61%)                   4    (27%) 
18   (29.5%)                7    (46.7%) 
36   (59%)                   7    (46.7%) 
6     (9.8%)                  1    (6.6%) 
1     (1.6%)                  0    (0%) 
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Figure Legends 
 
Figure 1A: Bland & Altman plot of the CRP concentration measured with 
the Nycocard and the reference test. 
 
Figure 1B: Bland & Altman plot of the CRP concentration measured with 
the QuikRead and the reference test. 
 
Figure 2A: Passing & Bablok regression plot of the Nycocard and the reference test. 
 
Figure 2B: Passing & Bablok regression plot of the QuikRead and the reference test. 
 
Figure 3: Distribution of CRP concentrations for each CRP test in the three categories not 
ill, slightly ill and ill (median, interquartile range, min-max). 
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Figure 1A  
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Figure 1B 
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Figure 2A 
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Figure 2B 
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Figure 3 
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